JP2013537426A5 - - Google Patents

Download PDF

Info

Publication number
JP2013537426A5
JP2013537426A5 JP2013524945A JP2013524945A JP2013537426A5 JP 2013537426 A5 JP2013537426 A5 JP 2013537426A5 JP 2013524945 A JP2013524945 A JP 2013524945A JP 2013524945 A JP2013524945 A JP 2013524945A JP 2013537426 A5 JP2013537426 A5 JP 2013537426A5
Authority
JP
Japan
Prior art keywords
adenovirus
cancer
item
orf3
impaired
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013524945A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013537426A (ja
JP5905460B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/048005 external-priority patent/WO2012024350A2/en
Publication of JP2013537426A publication Critical patent/JP2013537426A/ja
Publication of JP2013537426A5 publication Critical patent/JP2013537426A5/ja
Application granted granted Critical
Publication of JP5905460B2 publication Critical patent/JP5905460B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013524945A 2010-08-16 2011-08-16 抗がんアデノウイルス Active JP5905460B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37421510P 2010-08-16 2010-08-16
US61/374,215 2010-08-16
PCT/US2011/048005 WO2012024350A2 (en) 2010-08-16 2011-08-16 Anti-cancer adenoviruses

Publications (3)

Publication Number Publication Date
JP2013537426A JP2013537426A (ja) 2013-10-03
JP2013537426A5 true JP2013537426A5 (cg-RX-API-DMAC7.html) 2014-09-18
JP5905460B2 JP5905460B2 (ja) 2016-04-20

Family

ID=45605646

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013524945A Active JP5905460B2 (ja) 2010-08-16 2011-08-16 抗がんアデノウイルス

Country Status (10)

Country Link
US (1) US9187733B2 (cg-RX-API-DMAC7.html)
EP (1) EP2606137B1 (cg-RX-API-DMAC7.html)
JP (1) JP5905460B2 (cg-RX-API-DMAC7.html)
KR (1) KR101667094B1 (cg-RX-API-DMAC7.html)
CN (1) CN103180448B (cg-RX-API-DMAC7.html)
AU (1) AU2011292119B2 (cg-RX-API-DMAC7.html)
BR (1) BR112013003579A2 (cg-RX-API-DMAC7.html)
CA (1) CA2807778C (cg-RX-API-DMAC7.html)
SG (1) SG187785A1 (cg-RX-API-DMAC7.html)
WO (1) WO2012024350A2 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012024350A2 (en) * 2010-08-16 2012-02-23 Salk Institute For Biological Studies Anti-cancer adenoviruses
AU2013232101B2 (en) * 2012-03-13 2018-01-04 Salk Institute For Biological Studies Selective cell targeting using adenovirus and chemical dimers
KR102089121B1 (ko) 2013-03-14 2020-03-13 더 솔크 인스티튜트 포 바이올로지칼 스터디즈 종양살상형 아데노바이러스 조성물
WO2017062511A1 (en) 2015-10-05 2017-04-13 Salk Instutitute For Biological Studies Synthetic adenoviruses with tropism to damaged tissue for use in promoting wound repair and tissue regeneration
KR20180112024A (ko) 2016-02-23 2018-10-11 더 솔크 인스티튜트 포 바이올로지칼 스터디즈 바이러스 동역학에 미치는 영향 최소화를 위한 치료용 아데노바이러스의 외인성 유전자 발현
CA3013637A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
AU2017375633C1 (en) 2016-12-12 2023-04-27 Salk Institute For Biological Studies Tumor-targeting synthetic adenoviruses and uses thereof
CN110612116A (zh) 2017-05-08 2019-12-24 磨石肿瘤生物技术公司 甲病毒新抗原载体
AU2019251356B2 (en) 2018-04-09 2025-06-12 Salk Institute For Biological Studies Oncolytic adenovirus compositions with enhanced replication properties
TW202523847A (zh) * 2019-05-30 2025-06-16 美商磨石生物公司 經修飾之腺病毒

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA137094A (en) 1911-08-31 1911-11-28 Sheppe, Alice L. Cloth measuring and price calculating machine
FR2726285B1 (fr) * 1994-10-28 1996-11-29 Centre Nat Rech Scient Adenovirus depourvus de particules contaminantes viables, preparation et utilisation
DE69914382T2 (de) * 1998-07-07 2004-11-04 Transgene S.A. Verwendung der Leserahmen der adenoviralen E4-Region zur Verbesserung der Genexpression
EP1083229A1 (en) * 1999-09-10 2001-03-14 Introgene B.V. Modified adenoviral vectors for use in gene therapy
AU5882801A (en) * 2000-05-26 2001-12-03 Sumitomo Pharmaceuticals Company, Limited Novel recombinant adenovirus vector with relieved side effects
US20020106382A1 (en) * 2000-07-14 2002-08-08 Young Charles S.H. Modified adenovirus and uses thereof
US20030220284A1 (en) 2002-02-22 2003-11-27 Patricia Yotnda Delivery of adenoviral DNA in a liposomal formulation for treatment of disease
EP1499332A4 (en) 2002-04-29 2006-12-06 Hadasit Med Res Service COMPOSITIONS AND METHODS FOR TREATING CANCER WITH A VIRAL ONCOLYTIC AGENT
US20060099709A1 (en) 2002-10-01 2006-05-11 Chuan-Yuan Li Targeted tumor therapy by use of recombinant adenovirus vectors that selectively replicate in hypoxic regions of tumors
US20050201978A1 (en) 2003-11-17 2005-09-15 Lipton James S. Tumor and infectious disease therapeutic compositions
EP2352516A2 (en) * 2008-09-26 2011-08-10 Auburn University Immunization of avians by mucosal administration of non-replicating vectored vaccines
WO2012024350A2 (en) * 2010-08-16 2012-02-23 Salk Institute For Biological Studies Anti-cancer adenoviruses

Similar Documents

Publication Publication Date Title
JP2013537426A5 (cg-RX-API-DMAC7.html)
AR090470A1 (es) Vacuna contra el virus sincicial respiratorio (rsv)
MY183703A (en) Oncolytic adenovirus encoding a b7 protein
RU2016123086A (ru) Способы и композиции для лечения болезни хантингтона
WO2012142529A3 (en) Clonal strains of attenuated vaccinia viruses and methods of use thereof
EA201490004A1 (ru) Применение bifidobacterium lactis bl-04 для лечения заболеваний дыхательных путей
FR2981643B1 (fr) Procede de preparation d'un materiau composite silicium/carbone, materiau ainsi prepare, et electrode notamment electrode negative, comprenant ce materiau.
NZ748120A (en) Tri-segmented pichinde viruses as vaccine vectors
BR112014015016A8 (pt) Proteína homodimérica de duas cadeias de aminoácidos idênticas, cadeia de aminoácido, molécula de ácido nucléico, composição farmacêutica, célula hospedeira, método de preparação de uma proteína homodimérica, método para preparação de uma vacina, vacina e método de tratamento ou prevenção
JP2018512047A5 (cg-RX-API-DMAC7.html)
MX360045B (es) Combinaciones farmacéuticas de un inhibidor de cdk4/6 y un inhibidor de b-raf.
JP2011157399A5 (cg-RX-API-DMAC7.html)
BR112018074869A2 (pt) anticorpos antagonistas que ligam t ao tgfb1, tgfb2 e ao tgfb3 humanos e seu uso para o tratamento de fibrose pulmonar
PH12014500865A1 (en) Compounds and methods for enhancing innate immune responses
NZ628385A (en) Batches of recombinant adenovirus with altered terminal ends
MA39096B1 (fr) Anticorps spécifiques à fcrn
WO2018083220A3 (en) Replication-deficient arenavirus particles and tri-segmented arenavirus particles as cancer vaccines
BR112014029338A2 (pt) biomarcadores para determinação da resposta eficaz dos tratamentos de pacientes com carcinoma hepatocelular (hcc)
JP2018512597A5 (cg-RX-API-DMAC7.html)
MD4481B1 (ro) Herpesvirus recombinant Koi (KHV) şi vaccin pentru profilaxia bolii cauzate de KHV
JP2013544892A5 (cg-RX-API-DMAC7.html)
Hu et al. Oncolytic viruses for the treatment of bladder cancer: advances, challenges, and prospects
JP2015044878A5 (cg-RX-API-DMAC7.html)
JP2013100370A5 (cg-RX-API-DMAC7.html)
Du et al. Adenovirus-mediated expression of Bm K CT suppresses growth and invasion of rat C6 glioma cells